We are monitoring the impact of COVID-19 on Europe Angina Pectoris Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 8024
Share on
Share on

Europe Angina Pectoris Drugs Market Research Report – Segmented By Therapeutic Class & Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 8024
Pages: 145

The size of the European Angina Pectoris Drugs Market is estimated to grow at a promising rate between 2021 to 2026.

The rising burden with age, Y-O-Y growth in the incidence of coronary artery diseases, diabetes and hypertension, and heredity with heart diseases are likely to accelerate the European angina pectoris drugs market. Nearly half of the population in adults, 51.6% in Europe, were over-weight, as per Eurostat in 2016, increasing the growth among the obese people, which escalates the region's angina pectoris drugs market growth. Growth in the number of ischemia heart diseases is also elevating the growth rate of the market. Around 14.2 million people between 30-69 years lost their lives with various disorders like diabetes, arteriosclerosis, high cholesterol, stroke, and more are accelerating the angina pectoris drugs market growth in Europe during the analysis period. The presence of many domestic vital players and developments of novel drugs for treating diseases is escalating the market growth in the region.

The pricing pressure of the surgeries associated with heart diseases is limiting the angina pectoris drug market growth. Less per head income outgoings for healthcare are obstructing the market. Lack of efficiency and shortage of skilled professionals in clinical laboratories is to inhibit the growth. A strict and lengthy process for the approvals, which is a time-consuming process, restricts the market.

This research report on the European angina pectoris drugs market has been segmented & sub-segmented into the following categories:

By Therapeutic Class:

  • Beta-Blockers     
  • Calcium Antagonists      
  • Anticoagulants    
  • Anti-Platelets     
  • Others    

By Country:

  • United Kingdom
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Rest of Europe

Regionally, the European market is the second-largest market for angina pectoris drugs across the world. Factors such as favorable reimbursement policies, the Y-O-Y growth in the incidence of cardiovascular diseases in the European countries, and the growing aging population support the European angina pectoris drugs market further. The market in the UK and Germany is expected to have rapid growth in the angina pectoris market due to the introduction of new drug deliveries and regular FDA approvals. Moreover, increasingly common and regular angina pectoris, rising demand for altered diseases, and targeted treatments are factors flourishing the market further in Europe. Also, the accessibility of efficient treatment procedures is to accelerate the growth in the region successfully.

Some of the major companies dominating the European angina pectoris drugs market by their products and services include Sanofi, Bayer HealthCare, Cardeus Pharmaceuticals and CardioVascular BioTherapeutics (CVBT), Merck & Co. Inc., Anthera Pharmaceuticals, Cardium Therapeutics, Astellas Pharma, Ark Therapeutics Group plc, Torrent Pharmaceuticals Limited, Circ Pharma Limited, HUYA Bioscience International LLC, Lacer S.A., Viromed Co. Ltd., and Baxter Healthcare Corporation.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapeutic class                     

                                5.1.1 Introduction           

                                5.1.2 Beta blockers         

                                5.1.3 Calcium anatagonists          

                                5.1.4 Anticoagulants      

                                5.1.5 Anti platelets         

                                5.1.6 Others      

                                5.1.7  Y-o-Y Growth Analysis, By therapeutic class            

                                5.1.8  Market Attractiveness Analysis, By therapeutic class          

                                5.1.9 Market Share Analysis, By therapeutic class             

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By therapeutic class

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By therapeutic class

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By therapeutic class

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Anthera Pharmaceuticals                     

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Cardium Therapeutics                            

                8.3 Sanofi                           

                8.4 Bayer HealthCare                     

                8.5 Cardeus Pharmaceuticals                     

                8.6 Ark Therapeutics Group plc                 

                8.7 Torrent Pharmaceuticals Limited                       

                8.8 Circ Pharma Limited                

                8.9 Viromed Co. Ltd.                      

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Therapeutic Class, By Region along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

  1. Europe Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  2. Europe Beta blockers Market, By Region, From 2021 to 2026 (USD Million)
  3. Europe Calcium antagonists Market, By Region, From 2021 to 2026 (USD Million)
  4. Europe Anti coagulants Market, By Region, From 2021 to 2026 (USD Million)
  5. Europe Anti platelets Market, By Region, From 2021 to 2026 (USD Million)
  6. Europe Others Market, By Region, From 2021 to 2026 (USD Million)
  7. U.K. Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  8. Germany Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  9. France Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  10. Italy Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)
  11. Spain Angina Pectoris drugs Market, By Therapeutic class, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample